KDR and thymic carcinoma: Other interesting clinical trials are evaluating an nivolumab association with the VEGFR/PDGFR inhibitor vorolanib in thoracic tumors (NCT03583086) and atezolizumab monotherapy in thymic carcinoma (NCT04321330).